Loading clinical trials...
Loading clinical trials...
Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Conditions
Interventions
MA09-hRPE
Locations
3
United States
Jules Stein Eye Institute, UCLA School of Medicine
Los Angeles, California, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Wills Eye Institute-Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Start Date
July 11, 2012
Primary Completion Date
June 21, 2019
Completion Date
June 21, 2019
Last Updated
October 31, 2024
Lead Sponsor
Astellas Institute for Regenerative Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions